|本期目录/Table of Contents|

[1]韩忠政,李佩,陈钟,等.国内不同人群对粪菌移植的态度调查[J].医学研究与战创伤救治(原医学研究生学报),2017,19(03):225-230.[doi:10.3969/j.issn.1672-271X.2017.03.001]
　HAN Zhong-zheng,LI Pei,CHEN Zhong,et al.A survey of Chinese different populations views on fecal microbiota transplantation (FMT)[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2017,19(03):225-230.[doi:10.3969/j.issn.1672-271X.2017.03.001]
点击复制

国内不同人群对粪菌移植的态度调查()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第19卷
期数:
2017年03期
页码:
225-230
栏目:
出版日期:
2017-05-20

文章信息/Info

Title:
A survey of Chinese different populations views on fecal microbiota transplantation (FMT)
作者:
韩忠政; 李佩; 陈钟; 关富; 张鸣青
作者单位：363000漳州，厦门大学附属东南医院（解放军第175医院）消化内科
Author(s):
HAN Zhong-zheng;  LI Pei;  CHEN Zhong;  GUAN Fu;  ZHANG Ming-qing
（Department of Gastroenterology, the Affiliated Southeast Hospital of Xiamen University/the 175th Hospital of PLA, Zhangzhou 363000,Fujian, China）
关键词:
不同人群; 粪菌移植; 看法; 问卷调查
Keywords:
Different populations;  Fecal microbiota transplantations;  Views;  Questionnaire
分类号:
R574
DOI:
10.3969/j.issn.1672-271X.2017.03.001
文献标志码:
A
摘要:
目的 了解我国不同人群对粪菌移植这一新疗法的接受程度及担忧问题。方法 本次调查共设计了11道关于类菌移植的问题。调查方式包括通过QQ、微信两大社交平台进行网络调查和在厦门大学附属东南医院门诊及住院处进行直接调查。结果 本次调查共统计了428名参与者，包括100名医务人员、114名肠道疾病患者、82名患者家属及132名健康者。当他们患有肠道疾病时，71.26%参与者愿意将粪菌移植作为一种治疗方案，并且男性人数多于女性（76.11% vs 65.84%，P=0.019）。关于粪便供体的选取，57.94%参与者更愿意选择亲属作为供体，41.36%参与者会听取医师的推荐。选择粪菌移植的原因，69.86%参与者认为是由于传统药物治疗失败。结论 当患有肠道疾病时，多数人愿意去了解粪菌移植并接受其作为治疗方案。传统药物治疗失败及医师的推荐是人们选择粪菌移植的两个主要原因。感染到其他疾病则是人们对粪菌移植的最大担忧。
Abstract:
Objective To learn about the acceptability and concerns about FMT from Chinese different populations.Methods This questionnaire survey consists of 11 questions about FMT. We conducted a survey using social networks including QQ and Wechat and directly inquiring some people who are in outpatient clinic and hospitalized at the 175th Hospital of PLA.Results For this study, 428 individuals were surveyed including 100 medical staff, 114 patients, 82 family members of patients and 132 other healthy public. If they live with those intestinal diseases, 71.26% would be willing to undergo FMT as a treatment, and male participants were more likely to undergo FMT than female, 76.11% versus 65.84% (P=0.019). For donor selection, 57.94% of subjects preferred to have a family member as their fecal donor and 41.36% preferred whomever their doctor recommended. For some factors in considering FMT, 69.86% participants chose failure of conventional medications as an important factor.Conclusion In this survey, the large majority of participants were interested in or willing to consider FMT when they lived with those intestinal diseases. Failure of conventional medications and effectiveness and safety reportedly, were the two most important factors in considering FMT. The possibility of infecting with other diseases was key issues in considering FMT.

参考文献/References:

[1]Drekonja D, Reich J, Gezahegn S, et al. Fecal microbiota transplantation for clostridium difficile infection: a systematic review[J]. Ann Intern Med, 2015,162(9):630-638.
[2]Karadsheh Z, Sule S. Fecal transplantation for the treatment of recurrent clostridium difficile infection[J]. N Am J Med Sci, 2013,5(6):339-343.
[3]Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial[J]. Gastroenterology, 2015,149(1):102-109.
[4]Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis[J]. Gastroenterology, 2015,149(1):110-118.
[5]Cui B, Feng Q, Wang H, et al. Fecal microbiota transplantation through mid-gut for refractory crohns disease: safety, feasibility, and efficacy trial results[J]. J Gastroenterol Hepatol, 2015,30(1):51-58.
[6]Vrieze A, de Groot PF, Kootte RS, et al. Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease?[J] Best Pract Res Clin Gastroenterol, 2013,27(1):127-137.
[7]Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome[J]. Gastroenterology, 2012,143(4):913-916.
[8]Kao D, Roach B, Park H, et al. Fecal microbiota transplantation in the management of hepatic encephalopathy[J]. Hepatology, 2016,63(1):339-340.
[9]Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700-year-old fecal microbiota transplantation?[J] Am J Gastroenterol, 2012,107(11):1755-1756.
[10]Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis[J]. Surgery, 1958,44(5):854-859.
[11]Bakken JS. Fecal bacteriotherapy for recurrent clostridium difficile infection[J]. Anaerobe, 2009,15(6):285-289.
[12]Bakken JS, Borody T, Brandt LJ, et al. Treating clostridium difficile infection with fecal microbiota transplantation[J]. Clin Gastroenterol Hepatol, 2011,9(12):1044-1049.
[13]Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections[J]. Am J Gastroenterol, 2013,108(4):478-498.
[14]Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis[J]. J Crohns Colitis, 2014,8(12):1569-1581.
[15]Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: Indications, methodologies, mechanisms, and outlook[J]. Gastroenterology, 2015,149(1):223-237.
[16]Kahn SA, Gorawara-Bhat R, Rubin DT. Fecal bacteriotherapy for ulcerative colitis: Patients are ready, are we?[J] Inflamm Bowel Dis, 2012,18(4):676-684.
[17]Moses RE, McNeese LG, Feld LD, et al. Social media in the health-care setting: Benefits but also a minefield of compliance and other legal issues[J]. Am J Gastroenterol, 2014,109(8):1128-1132.
[18]戴菲菲，刘玉秀，苏义，等.网络环境下患者健康信息获取和医疗服务利用调查研究[J]. 医学研究生学报，2014，27（5）：517-520.
[19]Youngster I, Mahabamunuge J, Systrom HK, et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent clostridium difficile infection[J]. BMC Med, 2016,14(1):134.
[20]田宏亮, 丁超, 马春联, 等. 粪菌胶囊治疗慢传输型便秘15例临床疗效分析[J]. 中国实用外科杂志, 2016,36(4):430-432.
[21]闫晨, 曹海龙, 许梦雀, 等. 粪微生态肠溶胶囊的制备及其质量控制[J]. 中华消化杂志, 2016,36(6):407-411.

相似文献/References:

[1]彭丽娜综述,蔡淦,丛军审校.粪菌移植治疗溃疡性结肠炎的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2017,19(02):171.[doi:10.3969/j.issn.1672-271X.2017.02.015]

备注/Memo

备注/Memo:
基金项目：吴阶平医学基金会临床科研专项资助项目（320.6750.15231）
更新日期/Last Update: 2017-05-20